» Articles » PMID: 2820064

Chemotherapy of Endocrine Malignancies: a Review

Overview
Journal Semin Oncol
Specialty Oncology
Date 1987 Sep 1
PMID 2820064
Citations 13
Authors
Affiliations
Soon will be listed here.
Citing Articles

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Oronsky B, Ma P, Morgensztern D, Carter C Neoplasia. 2017; 19(12):991-1002.

PMID: 29091800 PMC: 5678742. DOI: 10.1016/j.neo.2017.09.002.


Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.

Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B Eur J Nucl Med Mol Imaging. 2015; 42(8):1238-46.

PMID: 25808630 DOI: 10.1007/s00259-015-3041-6.


Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.

Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C Onco Targets Ther. 2014; 7:1919-26.

PMID: 25364262 PMC: 4211616. DOI: 10.2147/OTT.S68573.


Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs.

Peixoto R, Noonan K, Pavlovich P, Kennecke H, Lim H J Gastrointest Oncol. 2014; 5(4):247-52.

PMID: 25083296 PMC: 4110496. DOI: 10.3978/j.issn.2078-6891.2014.019.


Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.

Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A Eur J Nucl Med Mol Imaging. 2014; 41(5):925-33.

PMID: 24504504 DOI: 10.1007/s00259-013-2677-3.